Literature DB >> 18523273

ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo.

Laurent Sabbagh1, Gayle Pulle, Yuanqing Liu, Erdyni N Tsitsikov, Tania H Watts.   

Abstract

During an acute immune response, CD8 T cells undergo rapid expansion followed by a contraction phase during which the majority of activated T cells die, leaving a few survivors to persist as memory cells. The regulation of T cell survival is critical at each stage of this response. 4-1BB, a TNFR family member, has been implicated in prolonging the survival of activated and memory CD8 T cells; however, the precise mechanisms by which 4-1BB sustains T cell survival are incompletely understood. Upon aggregation on T cells, 4-1BB associates with two TNFR-associated factors (TRAF), TRAF1 and TRAF2. TRAF2 is essential for downstream signaling from 4-1BB; however, the role of TRAF1 in 4-1BB signaling has not been elucidated and there have been conflicting data as to whether TRAF1 provides a positive or a negative signal in T cells. In this study, we report that TRAF1 plays a critical role in survival signaling downstream of 4-1BB during CD8 T cell expansion in response to viral infection in vivo. Further analysis reveals that TRAF1-deficient cells are impaired in their ability to up-regulate the prosurvival Bcl-2 family member Bcl-x(L) and show increased levels of the proapoptotic Bcl-2 family member Bim following 4-1BB signaling. TRAF1-deficient CD8 T cells fail to activate ERK in response to 4-1BB ligation and inhibition of ERK signaling downstream of 4-1BB in wild-type cells leads to increased Bim levels. Thus, TRAF1 has a prosurvival effect in CD8 T cells via the 4-1BB-mediated up-regulation of Bcl-x(L) and ERK-dependent Bim down-modulation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18523273     DOI: 10.4049/jimmunol.180.12.8093

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  67 in total

1.  Opposing roles for TRAF1 in the alternative versus classical NF-κB pathway in T cells.

Authors:  Ann J McPherson; Laura M Snell; Tak W Mak; Tania H Watts
Journal:  J Biol Chem       Date:  2012-05-08       Impact factor: 5.157

2.  The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease.

Authors:  Ali A Abdul-Sater; Maria I Edilova; Derek L Clouthier; Achire Mbanwi; Elisabeth Kremmer; Tania H Watts
Journal:  Nat Immunol       Date:  2016-11-28       Impact factor: 25.606

3.  4-1BB enhancement of CAR T function requires NF-κB and TRAFs.

Authors:  Gongbo Li; Justin C Boucher; Hiroshi Kotani; Kyungho Park; Yongliang Zhang; Bishwas Shrestha; Xuefeng Wang; Lawrence Guan; Nolan Beatty; Daniel Abate-Daga; Marco L Davila
Journal:  JCI Insight       Date:  2018-09-20

4.  CD2-mediated regulation of peripheral CD4(+)  CD25(+) regulatory T-cell apoptosis accompanied by down-regulation of Bim.

Authors:  Yuji Kashiwakura; Daisuke Sakurai; Yumiko Kanno; Masaaki Hashiguchi; Ayano Kobayashi; Akira Kurosu; Shogo Tokudome; Tetsuji Kobata; Hidefumi Kojima
Journal:  Immunology       Date:  2013-05       Impact factor: 7.397

5.  In vivo accumulation of T cells in response to IL-2/anti-IL-2 mAb complexes is dependent in part on the TNF family ligand 4-1BBL.

Authors:  Gloria H Y Lin; John C Stone; Charles D Surh; Tania H Watts
Journal:  Immunol Cell Biol       Date:  2011-09-27       Impact factor: 5.126

6.  Novel CD137 Gene Polymorphisms and Susceptibility to Ischemic Stroke in the Northern Chinese Han Population.

Authors:  Shuang Zhang; Zongmin Li; Ruyou Zhang; Xiaoying Li; Hewei Zheng; Qi Ma; Hui Zhang; Wenying Hou; Feng Zhang; Yingnan Wu; Litao Sun; Jiawei Tian
Journal:  Neuromolecular Med       Date:  2017-07-28       Impact factor: 3.843

Review 7.  Co-stimulatory and co-inhibitory pathways in cancer immunotherapy.

Authors:  Rachel E O'Neill; Xuefang Cao
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 8.  Immunometabolism: A new target for improving cancer immunotherapy.

Authors:  Chunqing Guo; Shixian Chen; Wenjie Liu; Yibao Ma; Juan Li; Paul B Fisher; Xianjun Fang; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2019-04-17       Impact factor: 6.242

Review 9.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

Review 10.  Memories that last forever: strategies for optimizing vaccine T-cell memory.

Authors:  Jeffrey D Ahlers; Igor M Belyakov
Journal:  Blood       Date:  2009-11-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.